PD-L1 And PIK3CA Testing Market Expected to Record Steady Growth and Approach $3.4 Billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The PD-L1 And PIK3CA Testing Market By The End Of 2030?

The pd-l1 and pik3ca testing market has experienced rapid expansion in recent years. This market is projected to expand from $1.67 billion in 2025 to $1.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. The historical growth of this market can be ascribed to several factors, including the development of pd-l1 and pik3ca assays, their increased adoption in clinical trials, the rising prevalence of cancer, continuous advancements in molecular diagnostics, and a growing awareness of personalized therapy.

The pd-l1 and pik3ca testing market is projected to experience swift expansion in the coming years. Its valuation is set to reach $3.4 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.2%. This expansion during the projection period stems from factors such as AI integration in biomarker identification, the increasing use of liquid biopsy applications, advancements in precision oncology, collaborations between diagnostic and pharmaceutical firms, and the regulatory clearance of next-generation assays. Key developments anticipated in this timeframe involve targeted cancer biomarker analysis, AI-driven mutation assessment, wider acceptance of liquid biopsy, synergy with pharmaceutical development, and extensive genomic screening.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28289&type=smp

Which Market Drivers Are Supporting The Expansion Of The PD-L1 And PIK3CA Testing Market?

The increasing prevalence of cancer is anticipated to drive the growth of the PD-L1 and PIK3CA testing market. Cancer is a condition defined by the uncontrolled proliferation and dissemination of abnormal cells within the body, which can invade adjacent tissues and potentially metastasize. The heightened cancer prevalence is attributable to rising lifestyle-related risks and an aging demographic, contributing to elevated diagnosis rates and an increased demand for early detection and effective treatment solutions. PD-L1 and PIK3CA testing supports cancer management through accurate diagnosis and guidance for targeted therapies, thereby personalizing treatment regimens for patients and improving clinical outcomes. For instance, in September 2024, according to the American Cancer Society, a US-based non-profit organization, global cancer cases in men is expected to rise by 84% by 2029, increasing from 10.3 million in 2022 to 19 million. Thus, the growing incidence of cancer is a key factor propelling the PD-L1 and PIK3CA testing market.

Which Segment Classifications Shape The PD-L1 And PIK3CA Testing Market?

The pd-l1 and pik3ca testing market covered in this report is segmented –

1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction

2) By Sample Type: Tissue Samples, Liquid Biopsy Samples

3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications

4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies

Subsegments:

1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis

2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing

3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction

How Are Trends Impacting The PD-L1 And PIK3CA Testing Market?

Leading companies within the PD-L1 and PIK3CA testing market are prioritizing technological innovations, such as companion diagnostic integration, to enhance therapeutic targeting, improve treatment efficacy, and support personalized medicine approaches in oncology. Companion diagnostic integration refers to advanced, technology-driven testing systems developed in conjunction with targeted medications to identify patient populations most likely to benefit from specific treatments based on their unique biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a Switzerland-based biotechnology and pharmaceutical company, introduced Itovebi (inavolisib) in combination with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The Food and Drug Administration (FDA), a US-based federal agency, approved this treatment regimen based on the pivotal Phase III INAVO120 study, which showed a more than doubled progression-free survival compared to palbociclib and fulvestrant alone. This marks Roche’s first targeted therapy for HR-positive disease and includes a companion diagnostic to pinpoint eligible patients, representing a significant stride in precision medicine for a patient demographic with limited initial treatment options.

Which Companies Are Expanding Their Footprint In The PD-L1 And PIK3CA Testing Market?

Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc.

Read the full pd-l1 and pik3ca testing market report here:

https://www.thebusinessresearchcompany.com/report/pd-l1-and-pik3ca-testing-global-market-report

How Is The PD-L1 And PIK3CA Testing Market Distributed Across Key Geographic Regions?

North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored PD-L1 And PIK3CA Testing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28289&type=smp

Browse Through More Reports Similar to the Global PD-L1 And PIK3CA Testing Market 2026, By The Business Research Company

Hpv Testing And Pap Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/hpv-testing-and-pap-test-global-market-report

D Dimer Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/d-dimer-testing-global-market-report

Direct To Consumer Dtc Laboratory Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/direct-to-consumer-dtc-laboratory-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795